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Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the 
chronically poor metabolic control that can result from T2DM is associated with a high risk for 
microvascular and macrovascular complications. Because of the progressive pathophysiology of 
T2DM, oral antidiabetic agents often fail to provide sustained glycemic control, indicating the 
need for new therapies. Saxagliptin (Onglyza; Bristol-Myers Squibb Company, Princeton, NJ, 
USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 
inhibitor, recently approved for the treatment of T2DM.
Evidence review: Saxagliptin significantly improves glycemic control vs placebo, as 
  demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial 
plasma glucose levels when used as monotherapy; in initial combination with metformin; and 
as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD). Saxagliptin 
also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, 
and has been shown to have cardiovascular safety.
Place in therapy: The clinical profile for saxagliptin indicates that it is useful as an adjunct 
to diet and exercise as first-line monotherapy and in combination with metformin; or as add-on 
treatment for patients who cannot achieve glycemic control with a combination of diet and 
lifestyle changes and metformin, SU, or TZD.
Keywords: dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1, HbA1c, incretin, saxagliptin
Core evidence place in therapy summary for saxagliptin 5 mg once-daily in adults 
with T2DM
Outcome measure Evidence Implications
Disease-oriented evidence
Reduction in HbA1c Clear Significantly improves glycemic control 
compared with placebo by decreasing HbA1c, 
as monotherapy; in initial combination with 
metformin; and as add-on therapy with 
metformin, SU, or TZD
Reduction in FPG and  
PPG-AUC
Clear Significantly decreases FPG and PPG-AUC 
compared with placebo as monotherapy; in 
initial combination with metformin; and as add-
on therapy to metformin, SU, or TZD
Glycemic controla 
Monotherapy  
Combination therapy
 
Clear  
Clear
Significantly more patients achieve  
HbA1c goal of , 7% compared with placebo 
Significantly more patients achieve HbA1c goal 
of , 7% in initial combination with metformin; 
and as add-on therapy to metformin, SU, or TZD 
compared with placebo
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Scope, aims, and objectives
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been added 
to the armamentarium of traditional antidiabetic medications 
and are currently recommended by the American   Association 
of Clinical Endocrinologists (AACE)/American College 
of Endocrinology (ACE) guidelines as an option for initial 
monotherapy in patients with glycated hemoglobin A1c 
(HbA1c) 6.5%–7.5%, and as part of combination treatment 
with metformin for patients with type 2 diabetes mellitus 
(T2DM) and an HbA1c $ 7.6%.1
Saxagliptin (Onglyza; Bristol-Myers Squibb Com-
pany, Princeton, NJ, USA; AstraZeneca   Pharmaceuticals 
LP, Wilmington, DE, USA) is a once-daily, oral DPP-4 
inhibitor that has been submitted for regulatory review in 
more than 50 countries and is approved in 38   countries, 
including the United States and member states of the 
  European Union, for patients with T2DM who are unable to 
(Continued)
Outcome measure Evidence Implications
Effects on postprandial 
insulin
Substantial Significantly increases postprandial insulin 
compared with placebo
Effects on postprandial 
glucagon
Substantial Significantly decreases postprandial glucagon 
compared with placebo
improvement in β-cell 
function
Substantial Saxagliptin monotherapy significantly improves 
β-cell function as assessed by HOMA-2β, and 
increases β-cell responsiveness as measured by 
hyperglycemic clamp compared with placebo
Patient-oriented evidence
Hypoglycemia Clear in multicenter, randomized, double-blind, 
24-week trials in which saxagliptin was 
administered as monotherapy; as initial 
combination with metformin; or as add-on 
treatment in patients receiving metformin, SU, 
or TZD; the frequency of hypoglycemia was 
generally low
weight effects Clear Saxagliptin is generally weight neutral
Tolerability Clear Saxagliptin is generally well tolerated, with 
adverse event frequencies similar to those 
observed with comparator when administered 
as monotherapy; as initial combination with 
metformin; or as add-on treatment in patients 
receiving metformin, SU, or TZD
Cv effects Substantial Post hoc analysis provided no evidence 
of increased Cv risk with saxagliptin as 
monotherapy or in combination with other oral 
antidiabetic agents. Results raise the possibility 
that saxagliptin may be cardioprotective
Patient adherence No evidence Studies required to assess effects of saxagliptin 
on adherence to treatment
Note: aPercentage of patients achieving HbA1c , 7%.
Abbreviations:  Cv,  cardiovascular;  FPG,  fasting  plasma  glucose;  HbA1c,  glycated  hemoglobin;  HOMA-2β, 
homeostatic model assessment-2 beta; PPG-AUC, postprandial glucose-area under the concentration–time curve; 
SU, sulfonylurea; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione.
maintain   glycemic control with diet and exercise alone or 
on metformin, a sulfonylurea (SU), or a   thiazolidinedione 
(TZD).2 In   addition to being well   tolerated without 
increasing the risk of hypoglycemia, saxagliptin produces 
significant reductions in HbA1c,   fasting plasma glucose 
(FPG), and postprandial glucose (PPG) levels when used 
as monotherapy and in   combination with metformin, 
SUs (eg, glyburide), and TZDs (eg, pioglitazone or 
rosiglitazone).2–7
The purpose of this article is to review the mechanism of 
action and current clinical evidence on saxagliptin as they 
relate to the management of patients with T2DM.
Methods
English language literature searches were conducted. 
Databases were searched between 1 January 2004 and 
9 November 2009, using the search terms “saxagliptin” OR Core Evidence 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
25
Saxagliptin: place in therapy review
“BMS-477118” and “type 2 diabetes”. Databases searched 
included the following:
•	 PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.
fgci)
•	 EMBASE
•	 BIOSIS
•	 Derwent Database
•	 Cochrane DSR (Database of Systematic Review)
•	 www.clinicaltrials.gov
•	 www.clinicalstudyresults.org
A total of 86 records were identified via the searches described 
above and manually reviewed. Thirty-eight of these records were 
duplicates and were not considered further. Twenty-seven were 
excluded for reasons including nonsystematic reviews, letters, 
editorials, news items, notes, comments, corrections, articles 
pertaining to other drugs or treatments, and articles on pharma-
cokinetics and drug interactions. This review is based on the 21 
records that comprised the evidence base (Figure 1).
Disease overview
Prevalence/economics
Diabetes has an estimated prevalence of 220 million 
people worldwide and is expected to affect approximately 
Full papers and
presentations (N = 86)
Records included
(n = 21)
Records 
excluded
Duplicate citations
(n = 38)
Other recordsa
(n = 27)
Level 1 clinical evidence
(systematic review, meta-analysis)
(n = 5)
Level 2 clinical evidence
(RCT)
(n = 11)
Level >3 clinical evidence
(trials other than RCT case reports)
(n = 3)
Evidence from animal and 
in vitro studies
(n = 2)
Economic evidence
(n = 0)
Figure 1 Evidence base included in the saxagliptin review. 
Notes: aincludes nonsystematic reviews, letters, editorials, news items, notes, comments, corrections, articles pertaining to other drugs or treatments, and articles on 
pharmacokinetics and drug interactions.
Abbreviation: RCT, randomized-controlled trial.
440   million by 2030.8 It is estimated that between 90% and 
95% of adults with diabetes have T2DM.9 The most recent 
estimate for the United States indicates that 23.7 million 
people have diabetes (both diagnosed and undiagnosed).10 
The prevalence of T2DM varies considerably, depending 
on race, ethnicity, age, and gender. In the United States, 
diabetes is more common among Native Americans, 
Alaska natives, Hispanics and Latinos, and non-Hispanic 
blacks.9,11 The prevalence of diabetes also increases with 
advancing age, reaching approximately 21% among those 
aged $ 60 years.11
Diabetes-related spending in the United States was esti-
mated to be $113 billion in 2009.10 The individual, societal, 
and economic burdens resulting from diabetes are mainly due 
to the long-term microvascular (eg, retinopathy, nephropathy) 
and macrovascular (eg, cardiovascular [CV]) complications 
of the disease.12,13
It is estimated that the number of people in the United 
States with diabetes will rise to 44.1 million by 2034 and 
that spending on this disease will subsequently increase to 
$336 billion.10 Various factors are expected to contribute to 
the rise in the United States prevalence of diabetes over the 
next 20 years, including the advancing age of the population Core Evidence 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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(diabetes prevalence increases with age); reduced mortality 
rates and longer patient life spans due to improved screening, 
detection, and better health care; and the increase in diabetes 
risk factors, most notably physical inactivity and obesity.11
T2DM risk factors and pathophysiology
Both genetic and environmental factors contribute to the 
development of T2DM.9,11 It is well known that multiple 
factors, including age, lack of physical activity, diet, and 
obesity strongly influence diabetes risk.14 Characteristics of 
the disease for most patients with T2DM are progressively 
impaired insulin secretion that reflects pancreatic β-cell 
dysfunction; increased hepatic glucose production; insulin 
resistance; increased free fatty acid levels, which contribute 
to insulin resistance; increased α-cell secretion of glucagon; 
increased glucose reabsorption by the kidneys; alterations 
in brain pathways involved in the regulation of appetite and 
satiety; and possibly decreased activity of incretin hormones 
(glucagon-like peptide-1 [GLP-1] and glucose-dependent 
insulin-releasing polypeptide [GIP]).11,15
Role of incretin therapy in treating  
the pathophysiology of T2DM
Incretins, intestinal hormones released in response to the 
ingestion of food, potentiate the glucose-induced insulin 
response. In humans, the incretin effect is mainly caused 
by 2 peptide hormones, GIP and GLP-1. GIP is secreted by 
K cells from the upper small intestine and GLP-1 is mainly 
produced in the enteroendocrine L cells located in the distal 
intestine. Circulating levels of GIP and GLP-1 are very low 
in the fasting state, and rapidly increase following food 
ingestion. The actions of the 2 peptides are similar. Both 
stimulate insulin secretion and promote β-cell proliferation. 
GLP-1 also binds to pancreatic β-cells to inhibit glucagon 
secretion along with other receptors in multiple tissues to 
slow gastric emptying, and increase satiety to decrease food 
ingestion (Figure 2A).16–20
Endogenous GLP-1 and GIP have half-lives of ,2 
  minutes and 5–7 minutes, respectively, before they are   rapidly 
degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely 
expressed in multiple tissues, including the central nervous 
system, kidney, lung, adrenal gland, liver, intestine, spleen, 
testis, and pancreas, as well as on the surfaces of lympho-
cytes and macrophages.16,17 As a result of DPP-4 degradative 
activity, intact and biologically active GLP-1 represents only 
10%–20% of total plasma GLP-1.20 By inhibiting the enzy-
matic activity of DPP-4, circulating plasma levels of active 
GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
The utility of DPP-4 inhibitors in the treatment of T2DM 
arises from their ability to prevent catabolism and prolong 
the actions of endogenous GIP and GLP-1 (Figure 2B).16–19 
Administration of a DPP-4 inhibitor doubles the   circulating 
levels of GLP-1 and increases the ratio of active/total 
  GLP-1.24 DPP-4 inhibitors enhance the actions ascribed to 
GLP-1 receptor agonists, including the stimulation of insulin 
and inhibition of glucagon secretion in a glucose-dependent 
manner, but are generally not associated with a deceleration 
of gastric emptying, satiety, or weight loss. This may explain 
the low incidence of gastrointestinal (GI) side effects with 
DPP-4 inhibitors.2,24,25
Saxagliptin is a potent, reversible, competitive DPP-4 
inhibitor that selectively inhibits DPP-4.16 This is in contrast 
to its effects on other DPP enzymes, including DPP-8 and 
DPP-9.16 Based on calculated binding affinities to DPP-4, 
saxagliptin is 10-fold more potent than either sitagliptin or 
vildagliptin, although this does not translate clinically.16,21,26 
Saxagliptin exhibits prolonged binding to the DPP-4 
active site, which results in an extended inhibition of this 
enzyme.16,26
In summary, inhibition of DPP-4 by saxagliptin slows 
the inactivation of incretin hormones, including GLP-1 and 
GIP, in T2DM patients.2 This inhibition results in increased 
A
Food
intake
Stomach
GI tract
Intestine
Incretins, which
include GLP-1 and 
GIP, are released
from the GI tract
after a meal
The actions of 
incretins are limited
because they are 
rapidly degraded by
the DPP-4 enzyme
Glucagon
secretion
GLP-1
GIP
Degraded incretins
Incretins
DPP-4 DPP-4
Insulin 
release
Pancreas
GLP-1 and GIP effect
on β-cells:
GLP-1 effect on 
α-cells:
β-cells
α-cells
Figure  2  Mechanism  of  action  of  DPP-4  inhibitors. A)  action  of  incretins.16–19 
B) action of DPP-4 inhibitors.16–19 Reprinted from Cell Metabolism, volume 3, Daniel J. 
Drucker, The biology of incretin hormones, 153–165, March 2006, with permission 
from Elsevier.18
Abbreviations: DPP-4, dipeptidyl peptidase-4; Gi, gastrointestinal; GiP, glucose-
dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1.
B Food
intake
Stomach
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  concentrations of active, intact, endogenous   incretin 
hormones, and greater duration and magnitude of their 
actions in increasing glucose-dependent insulin secretion 
and in suppressing glucagon secretion and hepatic glucose 
production.2,27
Current therapy options
Summary of glucose-lowering therapies
There are many treatment options that can be combined with 
lifestyle interventions to achieve glycemic control in patients 
with T2DM. Agents that can be used as monotherapy or 
in combination to lower blood glucose and HbA1c include 
biguanides (metformin), insulin, SUs (glyburide, glipizide, 
glibenclamide), TZDs (rosiglitazone, pioglitazone), GLP-1 
receptor agonists (exenatide, liraglutide), α-glucosidase 
inhibitors (acarbose), glinides (repaglinide, nateglinide), 
amylin agonists (pramlintide), DPP-4 inhibitors (eg, saxa-
gliptin, sitagliptin), bile acid sequestrants (colesevelam), and 
dopamine agonists (bromocriptine).1,12,28
In addition to lifestyle modification, which can lower 
HbA1c by 1%–2%, current treatment guidelines all recom-
mend metformin, unless contraindicated, as the first agent 
to be added to diet and lifestyle changes for the majority of 
patients.1,12 Metformin monotherapy typically lowers HbA1c 
by 1%–1.5%, is generally well tolerated with low risk for 
hypoglycemia, and is weight neutral.12 It is contraindi-
cated, however, in patients with renal insufficiency and its 
use is often associated with adverse GI effects.12 SUs also 
decrease HbA1c by about 1.5%, but their use is associated 
with hypoglycemia and weight gain.12 There is also evidence, 
primarily from in vitro and animal data, that exposure to SUs 
may be toxic to β-cells.15,29,30 Data from the A Diabetes Out-
come Progression Trial (ADOPT) also show that SUs have 
a higher secondary failure rate.31
TZDs lower HbA1c by 0.5%–1.5%, but their use has 
been associated with weight gain, edema, congestive heart 
failure, elevated risk for bone fractures, and possibly macular 
edema.12,32,33 Glinides lower HbA1c by 0.5%–1.5%, and their 
safety profile is similar to that of SUs, with hypoglycemia 
and weight gain as common adverse events (AEs).12 Acarbose 
lowers HbA1c by 0.5%–1.0% and the most common AEs are 
associated with GI disturbances.34 Pramlintide lowers HbA1c 
by 0.5%–1.0%, and GI events are the most common side 
effects associated with its use.12 GLP-1 receptor agonists have 
been shown to lower HbA1c levels by 0.5%–1.5%35 without 
increasing the risk of hypoglycemia, and are associated with 
weight loss. However, they are injectable medications, and 
the most common AEs include mild to moderate nausea.12 
Due to the progressive nature of diabetes, insulin therapy is 
ultimately required for many patients.11 AEs associated with 
insulin therapy include weight gain and hypoglycemia,12 
though the risks for both of these effects are reduced with 
the use of newer insulin analogs.36
Current treatment guidelines for patients with T2DM 
recommend an individualized treatment approach to balance 
glycemic efficacy with tolerability and long-term safety. 
Guidelines also consider that T2DM is a progressive disease 
characterized by worsening glycemic control, which requires 
treatment intensification with dose titration and the addition 
of medications over time to achieve and maintain treatment 
goals.12 Maintenance of glycemic control requires frequent 
(every 2–3 months) evaluation of treatment efficacy and 
prompt adjustment of the therapeutic regimen when patients 
are not achieving HbA1c goals.1
Clinical evidence with saxagliptin
Patient group/population
Patients included in well-controlled trial populations were 
treatment-naïve,3,4 or unable to maintain glycemic control 
with metformin,7 an SU,5 or a TZD in conjunction with 
diet and exercise.6 Pregnant women and pediatric patients 
aged ,18 years were excluded from the study population.2
Clinical efficacy
Saxagliptin has been studied as monotherapy and in combina-
tion with metformin, glyburide, and the TZDs (pioglitazone 
and rosiglitazone) and has demonstrated glycemic efficacy 
regardless of age, gender, race/ethnicity, or body mass index 
(BMI). Although the text reports on saxagliptin effects on 
glycemic parameters at doses ranging from 2.5 to 100 mg, 
efficacy results in Table 1 and Figure 3 are presented for 
saxagliptin 5 mg, the usual clinical dose for patients with 
T2DM.3–7,37–40
Monotherapy
12-week study
A randomized, parallel-group, double-blind, placebo-
  controlled trial included 338 treatment-naïve patients with 
T2DM and mean HbA1c 7.8% who received   saxagliptin 
2.5, 5, 10, 20, and 40 mg once-daily, or placebo, for 
12 weeks   (low-dose cohort). In addition, 85 patients received 
  saxagliptin 100 mg once-daily (high-dose cohort), or   placebo, 
for 6 weeks. Saxagliptin significantly reduced HbA1c by 
0.7%–0.9% vs placebo (−0.3%) from a mean baseline of 
7.9%.   Placebo-adjusted reductions in HbA1c ranged from 
0.45% to 0.63% (all doses P , 0.007 vs placebo).   Percentages Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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of patients with HbA1c , 7% at 12 weeks for the 2.5, 5, 10, 20, 
or 40 mg doses were 50, 47, 41, 50, and 53%, respectively, vs 
20% for placebo.38 Thus, clinically significant reductions from 
baseline HbA1c compared with placebo were demonstrated 
for 2.5–40 mg saxagliptin, with about 50% of patients in each 
treatment arm achieving the American Diabetes   Association/
European Association for the Study of Diabetes (ADA/
EASD) recommended glycemic target of HbA1c , 7%.12,38 
In addition, HbA1c was significantly reduced from baseline in 
the 100 mg cohort (−1.09%) compared with placebo (−0.36; 
P , 0.007).38 HbA1c reductions with saxagliptin monotherapy 
were particularly meaningful, given the relatively low mean 
baseline HbA1c (7.9%) of this study population.38
24-week study
A randomized, double-blind, placebo-controlled trial of 401 
patients with T2DM not controlled with diet and exercise 
alone (mean baseline HbA1c 7.9%) was conducted. Patients 
received oral saxagliptin 2.5, 5, or 10 mg once-daily or 
placebo for 24 weeks. Saxagliptin monotherapy produced 
clinically meaningful improvements in HbA1c and FPG in 
treatment-naïve patients at all doses (2.5, 5, and 10 mg) 
compared with placebo. Saxagliptin (5 and 10 mg) also 
statistically significantly improved PPG-area under the 
concentration–time curve (AUC) compared with placebo 
(P , 0.0002, P , 0.0001, respectively). A separate open-
label cohort of 66 patients with HbA1c 10%–12% received 
saxagliptin 10 mg once-daily for 24 weeks.3 Not surpris-
ingly, clinically meaningful reductions in HbA1c (−1.9%), 
FPG (−1.83 mmol/L), and PPG-AUC (−615 mmol.min/L) 
were also observed in the patients with high baseline HbA1c 
(10%–12%; Figure 4).3 Saxagliptin was more effective than 
placebo in achieving HbA1c , 7% at week 24.
Monotherapy titration study
A 24-week monotherapy study compared saxagliptin with 
placebo, as a fixed-dose and with titration, 2.5 mg daily before 
noon (QAM), 5 mg QAM, 5 mg daily after noon (QPM), 
and 2.5 mg titrated to 5 mg QAM (2.5/5 mg QAM) in 365 
treatment-naïve subjects with T2DM and inadequate glycemic 
control (mean baseline HbA1c 7.9%) on diet and exercise.39 
Statistically significant mean changes from baseline HbA1c 
were observed for 2.5 mg QAM (−0.71%; P = 0.0023), 
5 mg QAM (−0.66%; P = 0.0059), 2.5/5 mg QAM (−0.63%; 
P = 0.0119), and 5 mg QPM (−0.61%; P = 0.0157) vs 
  placebo (−0.26%). Respective reductions in FPG were −0.63 
(P = 0.0204), −0.59 (P = 0.0271), −0.69 (P = 0.0130), −0.44 
(P = NS), vs 0.18 mmol.min/L. A decrease in   PPG-AUC 
was observed in all treatment groups, with the greatest 
decreases in the   saxagliptin 2.5 mg QAM, 5 mg QAM, and 
2.5/5 mg QAM, and a   modest decrease in the 5 mg QPM vs 
placebo (−445, −456, −432, and −336 vs −171 mmol.min/L, 
respectively). The percentages of patients   achieving HbA1c 
, 7% with 2.5 mg QAM, 5 mg QAM, 2.5/5 mg QAM, and 
5 mg QPM, vs placebo were 35.8, 44.9, 43.5, and 38.6%, vs 
35.3%, respectively.39
Combination therapy
with metformin
Two clinical trials investigated the use of saxagliptin as an 
add-on to metformin or in combination as initial therapy. 
Both trials are described below.4,7,41
Add-on therapy
The efficacy of saxagliptin (2.5, 5, or 10 mg once-daily) or 
placebo when added to metformin (1,500–2,500 mg per day) 
was evaluated in a 24-week, randomized, double-blind, 
placebo-controlled study that included 743 patients 
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inadequately controlled on metformin alone (mean baseline 
HbA1c, 8.0%).7 Changes from baseline in HbA1c for metformin 
plus saxagliptin 2.5, 5, or 10 mg were −0.59, −0.69, −0.58%, 
respectively, vs a 0.13% increase for placebo (P , 0.0001 
for all saxagliptin doses vs placebo). The respective values 
for FPG were −0.79, −1.22, and −1.14, vs 0.07 mmol.min/L 
(all P , 0.0001); and for PPG-AUC were −493, −532, and 
−452, vs −183 mmol.min/L (all P , 0.0001). Saxagliptin 
added to metformin was also significantly more effective than 
metformin plus placebo in achieving HbA1c , 7.0%. Percent-
ages of patients receiving saxagliptin 2.5, 5, and 10 mg vs 
placebo added to metformin achieving this goal were 37, 44, 
and 44%, vs 17%, respectively (all P , 0.0001).7 Maximal 
HbA1c, FPG, and PPG-AUC reductions were observed with 
the saxagliptin 5-mg dose. Furthermore, add-on saxagliptin 
did not affect body weight compared with metformin plus 
placebo.7
In a subset of patients, β-cell assessment was conducted via 
homeostatic model assessment-2 beta (HOMA-2β) and dem-
onstrated that saxagliptin 2.5, 5, and 10 mg plus   metformin 
improved β-cell function. In addition,   saxagliptin added to 
metformin significantly increased postprandial insulin (P 
# 0.0001, P = 0.0063, P # 0.0001, respectively), C-peptide 
(P = 0.0003, P # 0.0001, P # 0.0001, respectively), and 
decreased postprandial glucagon (P = 0.0090, P = 0.0025, 
P = 0.0010, respectively) vs metformin alone.7
Patients who completed all visits during the initial 
24-week study period without need for hyperglycemia 
rescue therapy were eligible to enter a 78-week controlled 
long-term study extension. Patients who received saxagliptin 
in the initial 24-week study period maintained their current 
dosage in the long-term extension. At 102 weeks, treatment 
with saxagliptin 5 mg plus metformin was associated with a 
greater reduction in HbA1c than placebo plus metformin. At 
this time point, the placebo-corrected changes from baseline 
HbA1c for saxagliptin 2.5, 5, and 10 mg added to metformin 
were −0.62, −0.72, and −0.52%, respectively.37
initial combination therapy
Use of an initial combination of saxagliptin plus met-
formin was compared with the use of either agent alone 
in a randomized, double-blind, active-controlled trial that 
included 1,306 treatment-naïve patients with T2DM and 
baseline mean HbA1c of 9.4%, fasting C-peptide concen-
tration $ 1.0 ng/mL, and BMI # 40 kg/m2. Patients were 
randomized to 1 of 4   treatment arms: saxagliptin 5 mg plus 
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metformin 500 mg,   saxagliptin 10 mg plus metformin 500 mg, 
saxagliptin 10 mg plus   placebo, or metformin 500 mg plus 
placebo for 24 weeks.4 At 24 weeks, saxagliptin 5 mg plus 
 metformin, saxagliptin 10 mg plus metformin, saxagliptin 
10 mg, and metformin 500 mg reduced HbA1c by −2.5, −2.5, 
−1.7, and −2.0%, respectively (all P , 0.0001 for combina-
tion vs either agent alone). The respective values for FPG 
were −3.33, −3.44, −1.72, and −2.61 mmol.min/L (each com-
bination P , 0.0001 vs saxagliptin 10 mg; and P # 0.0002 
vs   metformin 500 mg). Percentages of patients achieving 
HbA1c , 7% were 60.3, 59.7, 32.2, and 41.1%, respectively, for 
saxagliptin 5 mg plus metformin, saxagliptin 10 mg plus met-
formin, saxagliptin 10 mg, and metformin 500 mg (P , 0.0001 
for each   combination vs monotherapy). The respective values 
for achievement of HbA1c # 6.5% were 45.3, 40.6, 20.3, and 
29.0% (P , 0.0001 for each combination vs monotherapy). 
All treatments reduced PPG-AUC; the respective declines were 
−1,170, −1,184, −891, and −833 mmol.min/L (all P , 0.0001 
for combination treatment vs monotherapy).4 Saxagliptin plus 
metformin initial combination therapy also provided significant 
improvements in β-cell function (HOMA-2β assessment) vs 
either agent alone, and numerically greater increases in post-
prandial insulin and early insulin responses were observed vs 
metformin, but not vs saxagliptin 10 mg. Similar to saxagliptin 
added to metformin, saxagliptin did not affect body weight 
compared with metformin alone.4 In summary, saxagliptin 
given in combination with metformin as initial therapy sig-
nificantly improved HbA1c, FPG, and PPG-AUC, compared 
with either agent alone, with a tolerability profile comparable 
to either of the monotherapy agents.4
with sulfonylurea
The efficacy of adding saxagliptin (2.5 or 5 mg once-daily) to 
glyburide (7.5 mg once-daily) vs uptitration of glyburide to a 
maximum of 15 mg once-daily was assessed in 768 patients 
with mean baseline HbA1c 8.4% receiving a submaximal 
dose of SU.5 Patients enrolled in the trial started treatment 
on saxagliptin 2.5 or 5 mg or placebo plus glyburide 7.5 mg, 
or glyburide 10 mg. Uptitration of glyburide to a maximum 
of 15 mg was permitted at weeks 2 and 4, based on FPG and 
fasting whole blood glucose levels for patients receiving 
this drug as monotherapy. At the end of the 24-week treat-
ment period, 92% of patients receiving glyburide only were 
uptitrated to a daily dose of 15 mg. The saxagliptin 2.5 and 
5 mg plus glyburide 7.5 mg treatment groups showed sta-
tistically significant adjusted mean decreases from baseline 
HbA1c and FPG vs the uptitrated glyburide group. Changes 
from baseline HbA1c with saxagliptin 2.5 and 5 mg plus 
  glyburide vs uptitrated glyburide were −0.54% and −0.64%, 
vs 0.08%, respectively (P , 0.0001 for both combinations 
vs uptitrated glyburide); and the respective values for 
FPG were −0.39 mmol/L, −0.56 mmol/L, vs 0.06 mmol/L 
(P = 0.0218 for 2.5 mg and P = 0.002 for 5 mg saxagliptin 
plus   glyburide vs uptitrated glyburide). The proportion of 
patients achieving HbA1c , 7% were 22.4% and 22.8%, 
vs 9.1%, respectively (both P , 0.0001), and the values 
for PPG-AUC were −238 and −278, vs 66 mmol.min/L, 
respectively (both P , 0.0001). In addition, 10.4% of patients 
treated with saxagliptin 5 mg plus glyburide achieved the 
HbA1c # 6.5% treatment goal, vs 4.5% for uptitrated gly-
buride (P = 0.0117).5 Mean body weight increases in the 
saxagliptin treatment group (2.5 and 5 mg) vs uptitrated 
glyburide were 1.5 lbs (0.7 kg; P = 0.0381) and 1.8 lbs (0.8 
kg; P = 0.0120), vs 0.7 lbs (0.3 kg), respectively. In summary, 
the saxagliptin 2.5 and 5 mg plus glyburide 7.5 mg treat-
ment groups showed statistically significant adjusted mean 
decreases from baseline in HbA1c and FPG vs the uptitrated 
glyburide group.5
Patients who met glycemic rescue criteria or completed 
all of their visits during the initial 24 week, short-term 
period were eligible to enter the 52-week study extension. 
As with the metformin long-term extension study, patients 
who received saxagliptin in the initial 24-week study period 
maintained their current dosage in the long-term extension. 
Treatment with saxagliptin 5 mg plus glyburide was associ-
ated with a greater reduction in HbA1c than placebo plus 
uptitrated glyburide sustained up to 76 weeks.40
with thiazolidinedione
The efficacy of saxagliptin plus TZD in patients with T2DM 
and inadequate glycemic control on TZD monotherapy was 
evaluated in a randomized, double-blind, placebo-controlled 
trial that included 565 patients with baseline mean HbA1c 
8.3% on stable monotherapy with pioglitazone 30 or 45 mg 
or rosiglitazone 4 or 8 mg for at least 12 weeks.6 Patients 
were randomized to 1 of 3 treatment arms: saxagliptin (2.5 
or 5 mg) or placebo and assessed for 24 weeks.6 At 24 weeks, 
the reductions in HbA1c for saxagliptin 2.5 and 5 mg plus 
TZD vs TZD alone were −0.66% (P = 0.0007 ) and −0.94% 
(P , 0.0001), vs −0.30%, respectively. The respective val-
ues for FPG vs TZD were −0.80 mmol/L (P = 0.0053) and 
−1.00 mmol.min/L (P = 0.0005), vs 0.20 mmol.min/L. The 
proportion of patients achieving HbA1c , 7.0% was 42.2% 
(P = 0.001) and 41.8% (P = 0.0013), vs 25.6%, respectively, 
for 2.5 and 5 mg saxagliptin plus TZD vs TZD alone. The 
respective values for achievement of HbA1c # 6.5% were Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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19.3% and 20.7%, vs 9.4%. Saxagliptin plus TZD was also 
significantly more effective than TZD alone in decreasing 
PPG-AUC.   Reductions from baseline for saxagliptin 2.5 
and 5 mg plus TZD vs TZD alone were −436 and −514, vs 
−149 mmol.min/L, respectively (P , 0.0001 for each com-
parison between saxagliptin plus TZD vs TZD alone).6 Saxa-
gliptin plus TZD also demonstrated significant improvements 
in β-cell function (HOMA-2β assessment), increases in post-
prandial insulin and C-peptide, and decreases in postprandial 
glucagon vs TZD monotherapy.6 In conclusion, saxagliptin 
plus TZD demonstrated statistically significant reductions in 
HbA1c, FPG, and PPG compared with TZD alone in patients 
inadequately controlled on TZD monotherapy.6
β-cell function
In addition to the improvements in β-cell function (HOMA-2β 
assessment) reported above, a significant improvement in 
β-cell responsiveness was demonstrated with use of saxa-
gliptin, utilizing the hyperglycemic clamp in treatment-naïve 
patients. This randomized, parallel-group, placebo-controlled 
study assessed the effect of saxagliptin 5 mg on β-cell 
function by intravenous hyperglycemic clamp (IV HC) in 
the fasting state (0–180 min IV HC) and after stimulating 
incretin secretion by orally ingesting 75 g glucose (180–480 
min IV oral HC) at baseline and after 12 weeks of saxagliptin 
treatment. Results showed that treatment with saxagliptin 
improved pancreatic β-cell responsiveness to glucose in the 
fasting and postprandial states and decreased postprandial 
glucagon concentration.22
Efficacy in elderly patients
The effects of saxagliptin treatment in elderly patients have 
been reported in a pooled subanalysis of elderly patients 
(aged $ 65 years) vs adults (aged , 65 years). Data from five 
24-week studies in which saxagliptin 5 mg or placebo was 
administered as monotherapy or added to treatment with met-
formin, glibenclamide, or a TZD were included. Results indi-
cated that saxagliptin lowered HbA1c by −0.73% vs −0.17% 
for placebo, and that the efficacy of saxagliptin was similar 
in adult (aged , 65 years) and elderly (aged $ 65 years) 
patients with T2DM.42
Safety and tolerability
As determined in 8 clinical trials, saxagliptin was generally 
well tolerated when administered as monotherapy or combined 
with metformin, glyburide, or a TZD (Figure 3).3–7,37,39,40 AEs 
observed in $ 5% of patients in any treatment group in the 
pivotal trials for saxagliptin are   summarized in Tables 2 and 3. 
The most common AEs observed with   saxagliptin are similar 
to those of other DPP-4 inhibitors, and include   headache, 
upper respiratory tract infections, urinary tract infections, 
and nasopharyngitis.3–7,37,43,44 Addition of saxagliptin to 
metformin was generally well tolerated, with no increase in 
hypoglycemia or weight over 102 weeks.37 Combination of 
saxagliptin 5 mg plus TZD resulted in increased peripheral 
edema vs TZD alone (8.1% vs 4.3%, Table 2). However, 
peripheral edema was less common with saxagliptin 2.5 mg 
plus TZD vs TZD monotherapy (3.1% vs 4.3%). When pedal 
edema was excluded from the analysis, the frequencies for 
edema were 0.5% each for all saxagliptin-treated patients 
and those who received TZD alone.6 Although the long-term 
clinical safety, tolerability, and efficacy of DPP-4 inhibitors 
have been demonstrated for up to 2 years, it is unclear if there 
are long-term neurological or immunological consequences 
of inhibiting DPP-4.45–48
Hypoglycemia
In the 8 multicenter, randomized, double-blind, 24-week, 
phase 3 trials in which saxagliptin was administered as 
monotherapy; as initial combination with metformin; or as 
add-on treatment in patients receiving metformin, glyburide, 
or TZD, the frequency of hypoglycemia was generally simi-
lar to that for placebo or to treatment arms not containing 
saxagliptin for up to 76 weeks (Table 3).3–7,37,39,40,49 Note that 
significance values were not determined. The results from the 
pooled analysis of the monotherapy study, as well as the initial 
combination and add-on studies, concluded that saxagliptin 
had a low risk of hypoglycemia when used as monotherapy or 
in combination with metformin, SUs, or TZDs. Specifically, 
hypoglycemia was confirmed in ,2.5% of patients treated 
with saxagliptin 2.5, 5, or 10 mg plus metformin or metformin 
monotherapy.49
Cardiovascular data
In December 2008, the US Food and Drug Administration 
(FDA) published guidance for the evaluation of CV safety 
of agents being developed for the treatment of T2DM. This 
guideline included a recommendation that sponsors perform 
a meta-analysis of the important CV events across phase 2 and 
phase 3 controlled clinical trials, and explore similarities and/or 
differences in subgroups (eg, age, sex, race), if possible. In addi-
tion, sponsors should compare the incidence of important CV 
events occurring with the investigational agent to the incidence 
of the same types of events occurring with the control group 
to show that the upper bound of the 2-sided 95% confidence 
interval (CI) for the estimated risk ratio was , 1.8.50Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Although the application for saxagliptin approval was 
filed before this guidance was issued by the FDA, the 
  sponsors conducted a post hoc meta-analysis using the 
phase 2b/3 data from 8 randomized, double-blind trials for 
saxagliptin.3–7,37,39,40,51 For this analysis, the primary end point 
was major adverse cardiovascular events ([MACE] stroke, 
myocardial infarction, or CV death) and acute cardiovascular 
events ([ACE] clinically significant events, including cardiac 
revascularization procedures). The analysis included 4,607 
patients (3,206 randomized to saxagliptin 2.5, 5, or 10 mg; 
150 randomized to saxagliptin 20, 40, or 100 mg; and 1,251 
randomized to placebo, metformin, or uptitrated glyburide). 
Within the saxagliptin population, 81% of patients had at 
least 1 CV risk factor in addition to diabetes; hypertension 
(52%); hypercholesterolemia, including mixed dyslipidemia 
(44%); or a history of smoking (39%). The Cox proportional 
hazard ratio was 0.44 (95% CI, 0.24–0.82) for MACE and 
0.59 (95% CI, 0.35–1.00) for ACE for saxagliptin vs other 
treatment arms (Table 4). These results support the conclu-
sion that there was no evidence of increased CV risk with 
saxagliptin as monotherapy or in combination with other 
oral antidiabetic agents when used for up to 2.5 years.51 To 
fulfill the FDA’s requirement to demonstrate the exclusion of 
CV risk, a prospective outcomes study to evaluate potential 
cardioprotective effects in saxagliptin-treated patients is 
currently underway. The anticipated study completion date 
is 2015 and results are expected thereafter.52
Drug interactions
Data from in vitro studies revealed that saxagliptin and 
5-hydroxy saxagliptin did not inhibit cytochrome P450 
(CYP)1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4, or 
induce CYP1A2, 2B6, 2C9, or 3A4. Therefore, saxagliptin 
is not expected to alter the metabolic clearance of coad-
ministered drugs that are metabolized by these enzymes.2 
Saxagliptin metabolism is primarily mediated by CYP3A4/5 
and 5-hydroxy saxagliptin, a major metabolite of saxagliptin, 
also a DPP-4 inhibitor. Saxagliptin does not meaningfully 
alter the pharmacokinetics of CYP3A4/5 inducers (eg, 
rifampin), metformin, glyburide, pioglitazone, or digoxin, nor 
does it alter simvastatin, diltiazem, or ketoconazole, which 
have CYP3A4/5-mediated metabolism.2 Significant increases 
in plasma concentrations of saxagliptin are anticipated with 
strong CYP3A4/5 inhibitors (eg, atazanavir, clarithromycin, 
indinavir, itraconazole, nefazadone, nelfinavir, ritonavir, 
saquinavir, and telithromycin). Therefore, the dose of saxa-
gliptin should be limited to 2.5 mg when coadministering it 
with a strong CYP3A4/5 inhibitor.2Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Although saxagliptin is a P-glycoprotein (P-gp) substrate, 
it is not a significant inhibitor or inducer of P-gp. The in vitro 
protein binding of saxagliptin and 5-hydroxy saxagliptin 
in human serum is minimal. Thus, protein binding is not 
expected to have a meaningful impact on the pharmacokinet-
ics of saxagliptin or other drugs.2
Dosage, administration,  
and formulations
The recommended dose of saxagliptin is 2.5 or 5 mg once-
daily, taken regardless of meals. No dosage adjustment 
is required for patients with hepatic impairment or for 
those with mild renal insufficiency (creatinine   clearance 
[CrCl] . 50 mL/min). However, 2.5 mg daily is   recommended 
for patients with moderate-to-severe renal impairment or 
end-stage renal disease (CrCl # 50 mL/min). Renal func-
tion should be assessed prior to initiation of treatment with 
saxagliptin and periodically thereafter. Saxagliptin appears to 
be an   effective treatment in adults of any age; however, care 
should be taken in dose selection in the elderly.2 A saxagliptin 
dose of 2.5 mg daily is also recommended for patients taking 
strong CYP3A4/5 inhibitors, such as ketoconazole.2
Alternative to other oral 
antidiabetic drug classes
Newer antidiabetic medications may offer less complex 
  regimens with fewer side effects than traditional oral 
Table 3 Hypoglycemia in pooled analysis of saxagliptin monotherapy and combination studiesa,3–7,37
Trial Drug/dosea Reported hypoglycemiab (%) Confirmed hypoglycemiac (%)
Monotherapy
SAXA 2.5 mg 2.9 None
SAXA 5 mg 4.7 None
SAXA 10 mg 8.2 None
PBO 6.3 None
Add-on combination
  with MET SAXA 2.5 mg + MET 7.8 0.5
SAXA 5 mg + MET 5.2 0.5
SAXA 10 mg + MET 3.9 0.6
PBO + MET 5.0 0.6
  with SU
SAXA 2.5 mg + GLY 13.3 2.4
SAXA 5 mg + GLY 14.6 0.8
PBO + UP-GLY 10.1 0.7
  with TZD
SAXA 2.5 mg + TZD 4.1 0.5
SAXA 5 mg + TZD 2.7 0
PBO + TZD 3.8 0
initial combination
  with MET (24 wks) SAXA 5 mg + MET 3.4 0
SAXA 10 mg + MET 5.0 0.6
SAXA 10 mg  1.5 0
PBO + MET 4.0 0.3
  with MET (102 wks)
SAXA 2.5 mg + MET 10.4 1.0
SAXA 5 mg + MET 8.9 1.0
SAXA 10 mg  11.0 1.1
PBO + MET 10.1 0.6
Notes: aData from the saxagliptin monotherapy QAM and QPM study, as well as the saxagliptin + SU extension study were not available. bReported hypoglycemia was defined 
as events consistent with symptoms of hypoglycemia with or without documented blood glucose levels. cConfirmed hypoglycemia was defined by a fingerstick glucose value 
of , 50 mg/dL with associated symptoms.
Abbreviations: GLY, glyburide; MET, metformin; PBO, placebo; SAXA, saxagliptin; TZD, thiazolidinedione; UP-GLY, uptitrated glyburide.
Table 4 Cardiovascular events in the phase 2b/3 clinical trial program 
for saxagliptin51
Event type, n (%) Saxagliptin (n = 3,356) Control (n = 1,251)
ACE 38 (1.1) 23 (1.8)
MACE 23 (0.7) 18 (1.4)
All death 10 (0.3) 12 (1.0)
Cv death 7 (0.2) 10 (0.8)
Abbreviations: ACE, acute cardiovascular event; MACE, major adverse cardio-
vascular event; Cv, cardiovascular.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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  antidiabetic drugs. As a consequence, adherence to therapy 
and improved HbA1c control would be anticipated.53
Guidelines set forth by the AACE/ACE recognize the 
value of DPP-4 inhibitors, noting that they reduce both FPG 
and PPG and may be used in combination with metformin. 
The guidelines specifically recommend DPP-4 inhibitors 
as monotherapy for patients with HbA1c levels between 
6.5% and 7.5%, as part of 2-drug combination therapy with 
  metformin in patients with HbA1c levels between 7.6% and 
9.0%, and as part of triple combination therapy (eg, with 
metformin and a TZD) for patients with HbA1c . 9.0%.1 
The guidelines also note that these agents have low risk for 
hypoglycemia and no long-term toxicities to date.1
ADA/EASD 2009 guidelines do not consider DPP-4 
inhibitors as preferred (ie, tier 1 or tier 2) interventions 
because at the time of publication, DPP-4 inhibitors were 
considered too new and their long-term safety was still 
undetermined.12 However, these guidelines take note of the 
fact that DPP-4 inhibitors lower HbA1c levels by 0.6%–0.9%, 
are weight neutral, and are not associated with hypoglycemia 
when used as monotherapy.12
Emerging role of combination 
therapy
In addition to the emerging role of DPP-4 inhibitors as initial 
therapy, combination therapy is recommended by AACE/
ACE for patients with HbA1c $ 7.6%.1 When patients are 
unsuccessful in achieving or sustaining their HbA1c goals with 
lifestyle intervention and appropriately titrated monotherapy, 
advancement to dual therapy should be considered.1 The 
ADA/EASD recommendations also indicate that if lifestyle 
intervention and the maximum tolerated dose of metformin 
fail to achieve or sustain glycemic goals, another medication 
should be added within 2–3 months of treatment initiation or 
at any time the target HbA1c is not achieved.12 The   treatment 
algorithm put forward as part of the Banting Lecture by 
Dr Ralph DeFronzo in 2009 also favored combination therapy 
for the treatment of  T2DM, noting that combination treat-
ment based on the reversal of known pathophysiological 
defects provides greater potential for the achievement of 
sustained glycemic control.15
Place in therapy
Although metformin continues to be the recommended 
first-line agent for patients with T2DM, the value of DPP-4 
inhibitors is becoming increasingly recognized in current 
treatment algorithms as first-line treatment and second-line 
treatment options due to their efficacy (including HbA1c 
control and preferential targeting of PPG) and well-tolerated 
profile. Saxagliptin is a DPP-4 inhibitor indicated as an 
adjunct to diet and exercise to improve glycemic control in 
adults with T2DM.2 Saxagliptin has been studied as mono-
therapy and in combination with metformin, glyburide, and 
TZD (pioglitazone and rosiglitazone) therapy.3–7 When given 
as monotherapy, in initial combination with metformin, or 
in combination as add-on therapy for patients inadequately 
controlled with an SU or TZD in studies up to 24 weeks, 
and metformin up to 102 weeks, saxagliptin has docu-
mented efficacy in improving glycemic control (measured 
by HbA1c, FPG, PPG, and proportions of patients achieving 
HbA1c , 7%) compared with placebo. Saxagliptin is gener-
ally well tolerated, and is weight neutral with a low risk of 
hypoglycemia.3–7,37,39,47 The current evidence base supports 
use of saxagliptin in adult patients with diabetes in a broad 
range of patient types, as demonstrated by similar efficacy 
and tolerability regardless of age, gender, race/ethnicity, or 
BMI. In addition to its efficacy and safety profile, saxagliptin 
has also shown no risk of cardiac AEs.51 An outcome study is 
currently being conducted to further evaluate CV risk and to 
assess a potential cardioprotective effect of saxagliptin.52
Unmet needs
Efficacy
The long-term efficacy of traditional oral antihyperglycemic 
medications is variable, and approximately half of patients 
do not achieve durable glycemic control.16,54 Since as many 
as 90%–95% of patients with T2DM are also overweight or 
obese, it is imperative to implement lifestyle modifications 
to target not only the glycemic control in these patients, 
but also the hypertension, hyperlipidemia, and other CV 
risk factors often associated with obesity. However, in the 
majority of patients with T2DM, lifestyle modifications fail 
to achieve or maintain glycemic goals due to a   combination of 
  factors, including the failure to lose weight, weight regain, or 
  progressive disease.12 Long-term glycemic control is difficult 
to sustain with oral antidiabetic drugs because progressive 
β-cell dysfunction is characteristic of T2DM, especially if the 
diagnosis is delayed.16 Results from 1 analysis   demonstrated 
that the 5-year failure rates (defined as FPG . 10 mmol/L 
for 2 clinic visits in a row) for the TZD (rosiglitazone), 
metformin, and the SU (glyburide), were 15, 21, and 34%, 
respectively.31 The limited long-term efficacy of these thera-
pies underscores the significant need for new medications 
with novel mechanisms of action, as well as the need for 
combinations of agents targeting the multiple pathologies 
underlying T2DM.12,15Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Summary
In summary, saxagliptin provides significant and clinically 
meaningful benefit with respect to glucose control, signifi-
cantly reducing HbA1c by 0.5%–2.5%, as monotherapy and 
in combination therapy without compromising tolerability. 
Notably, the drop in HbA1c is highly correlated with results 
from the saxagliptin clinical trial program, which, taken 
together with current treatment guideline recommendations 
(AACE/ACE), supports a place for saxagliptin as a possible 
alternative to first-line treatment and second-line treatment 
options, including use as monotherapy in patients with 
HbA1c 6.5%–7.5%, and in combination with other agents 
when HbA1c . 6.5%. In addition, AACE/ACE recommends 
the use of DPP-4 inhibitors vs other oral agents in patients 
when HbA1c is in the range of 6.5%–7.5% and FPG and PPG 
levels are elevated.1
Acknowledgments
Funding for this review was provided by Bristol-Myers 
Squibb and AstraZeneca. Technical and editorial assistance 
for this manuscript was provided by Gina Coviello, MS, 
Quintiles, Parsippany, NJ, USA.
Disclosure
Steven Edelman, MD, is on the speaker’s bureau and a 
consultant for Eli Lilly and Company, Merck & Co. Inc., 
sanofi-aventis, Takeda Pharmaceuticals, GlaxoSmithKline, 
Novo Nordisk, and Amylin Pharmaceuticals. Kristen Kulasa, 
MD, reports no conflicts of interest.
References
1.  Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an 
American Association of Clinical Endocrinologists/American College of 
  Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm 
for glycemic control. Endocr Pract. 2009;15(6):541–559.
2.  Onglyza [package insert]. Princeton, NJ/Wilminton, DE: Bristol-Myers 
Squibb Company/AstraZeneca Pharmaceuticals LP; July 2009.
3.  Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin 
monotherapy in treatment-naive patients with type 2 diabetes. Curr Med 
Res Opin. 2009;25:2401–2411.
4.  Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in 
combination with metformin as initial therapy improves glycemic   control 
in patients with type 2 diabetes compared with either monotherapy: 
a   randomized controlled trial. Diabetes Obes Metab. 2009;11(6): 
611–622.
5.  Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a 
  submaximal dose of sulphonylurea improves glycaemic   control 
  compared with uptitration of sulphonylurea in patients with type 2 
diabetes: a   randomised controlled trial. Int J Clin Pract. 2009;63(9): 
1395–1406.
6.  Hollander P, Li J, Allen E, Chen R; for the CV181-013 investigators. 
Saxagliptin added to a thiazolidinedione improves glycemic control in 
patients with type 2 diabetes and inadequate control on thiazolidinedione 
alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819.
  7.  DeFronzo RA, Hissa M, Garber AJ, et al. The efficacy and safety 
of saxagliptin when added to metformin therapy in patients with 
  inadequately controlled type 2 diabetes on metformin alone. Diabetes 
Care. 2009;32(9):1649–1655.
  8.  World Health Organization (WHO) Media Centre. Diabetes fact sheet. 
World Health Organization. Available from: http://www.who.int/
mediacentre/factsheets/fs312/en/. Accessed Jun 21, 2010.
  9.  National Diabetes Information Clearinghouse. National Diabetes 
  Statistics, 2007. National Institute of Diabetes and Digestive and 
Kidney Diseases, US Department of Health and Human Services, and 
National Institutes of Health. NIH Publication No. 08-3892. 2008. 
Bethesda, MD.
  10.  Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future 
diabetes population size and related costs for the U.S. Diabetes Care. 
2009;32(12):2225–2229.
  11.  Edelman SV, Henry RR. Diagnosis and Management of Type 2 
  Diabetes. West Islip, NY: Professional Communications, Inc; 2007.
  12.  Nathan DM, Buse JB, Davidson MB, et al. Medical management of 
hyperglycemia in type 2 diabetes: a consensus algorithm for the initia-
tion and adjustment of therapy: a consensus statement of the American 
Diabetes Association and the European Association for the Study of 
Diabetes. Diabetes Care. 2009;32(1):193–203.
  13.  Blonde L. State of diabetes care in the United States. Am J Manag Care. 
2007;13(2):S36–S40.
  14.  van Tilburg J, van Haeften TW, Pearson P, Wijmenga C. Defining 
the genetic contribution of type 2 diabetes mellitus. J Med Genet. 
2001;38(9):569–578.
  15.  DeFronzo RA. Banting Lecture. From the triumvirate to the ominous 
octet: a new paradigm for the treatment of type 2 diabetes mellitus. 
Diabetes. 2009;58:773–795.
  16.  Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 
inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009; 
26(3):249–262.
  17.  Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and 
GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008;34 
Suppl 2:S65–S72.
  18.  Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3): 
153–165.
  19.  Barnett A. DPP-4 inhibitors and their potential role in the management 
of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470.
  20.  Kulasa KM, Henry RR. Pharmacotherapy of hyperglycemia. Expert 
Opin Pharmacother. 2009;10(15):2415–2432.
  21.  Kirby M, Ming Tse Yu D, O’Connor S, Gorrell M. Inhibitor selectivity 
in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci. 
2010;118(1):31–41.
  22.  Henry R, Smith S, Schwartz S, et al. β-cell stimulation by saxagliptin 
in patients with type 2 diabetes. Diabetes. 2009;58 Suppl 1:447-P.
  23.  Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV 
inhibitor, improves model-assessed beta-cell function in patients with 
type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888–4894.
  24.  Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 
diabetes? Neth J Med. 2007;65:60–64.
  25.  Nicolucci A, Rossi MC. Incretin-based therapies: a new potential 
  treatment approach to overcome clinical inertia in type 2 diabetes. Acta 
Biomed. 2008;79(3):184–191.
  26.  Wang A, Dorso C, Kopcho L, et al. Implications of the prolonged 
  dissociation rate of saxagliptin, a highly potent and selective DPP4 inhib-
itor, on plasma DPP measurements. Diabetes. 2008;57:A576–A577.
  27.  Prins JB. Incretin mimetics and enhancers: mechanisms of action. Aust 
Prescr. 2008;31:102–104.
  28.  Scranton R, Cincotta A. Bromocriptine–unique formulation of dopamine 
agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 
2010;11(2):269–279.
  29.  Rustenbeck I, Wienbergen A, Bleck C, et al. Desensitization of insulin 
secretion by depolarizing insulin secretagogues. Diabetes. 2004;53 
Suppl 3:S140–S150.Core Evidence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/core-evidence-journal
Core Evidence is an international, peer-reviewed open-access journal 
evaluating the evidence underlying the potential place in therapy of 
drugs throughout their development lifecycle from preclinical to post-
launch. The focus of each review is to evaluate the case for a new drug 
or class in outcome terms in specific indications and patient groups. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Core Evidence 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
37
Saxagliptin: place in therapy review
  30.  Donath MY, Ehses JA, Maedler K, et al. Mechanisms of β-cell death 
in type 2 diabetes. Diabetes. 2005;54:S108–S113.
  31.  Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of 
rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 
2006;355(23):2427–2443.
  32.  Avandia [package insert]. Research Triangle Park, NC:   GlaxoSmithKline; 
Feb 2009.
  33.  Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone   hydroc  hloride 
monotherapy improves glycemic control in the treatment of patients 
with type 2 diabetes: a 6-month randomized placebo-controlled 
  dose-response study. The Pioglitazone 001 Study Group. Diabetes 
Care. 2000;23(11):1605–1611.
  34.  Precose [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals 
Inc.; Aug 2008.
  35.  Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus 
twice daily for the treatment of type 2 diabetes: a randomised,   open-label, 
non-inferiority study. Lancet. 2008;372(9645):1240–1250.
  36.  Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin 
analogues and premixed insulin analogues over human insulins: impact 
on efficacy and safety. Am J Med. 2008;121 Suppl 6:S9–S19.
  37.  DeFronzo R, Hissa MN, Garber AJ, et al. Once-daily saxagliptin added 
to metformin provides sustained glycemic control and is well tolerated 
over 102 weeks in patients with type 2 diabetes. Diabetes. 2009;58 
Suppl 1:547-P.
  38.  Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the 
dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with 
type 2 diabetes. Diabetes Obes Metab. 2008;10:376–386.
  39.  Bristol-Myers Squibb. Study of BMS-477118 as monotherapy with 
titration in subjects with type 2 diabetes who are not controlled with diet 
and exercise. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National 
Library of Medicine (US). 2009-[cited 2010 May 5]. Available from: 
http://www.clinicaltrials.gov/ct2/show/study/NCT00316082 NLM 
Identifier: NCT00316082.
  40.  Bristol-Myers Squibb Company. A multicenter, randomized, double-
blind, placebo-controlled phase 3 trial to evaluate the efficacy and 
safety of saxagliptin in combination with glyburide in subjects with 
type 2 diabetes who have inadequate glycemic control on glyburide 
alone. ClinicalStudyResults org Web site. Available from: http://
www.  clinicalstudyresults.org/documents/company-study_9577_7.pdf. 
Accessed Jun 21, 2010.
  41.  Chen R, Xu Z, Duan Y, et al. Reaching HbA1c goals with saxagliptin in 
combination with metformin or sulfonylurea. Diabetologia. 2009;52 
Suppl 1:1–550. S753.
  42.  Maheux P, Doucet J, Allen E, et al. Efficacy and safety of saxagliptin 5 
mg once-daily therapy in elderly patients with type 2 diabetes mellitus. 
Diabetologia. 2008;52 Suppl 1:1–550. S302.
  43.  Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy 
in type 2 diabetes: systematic review and meta-analysis. JAMA. 
2007;298(2):194–206.
  44.  Januvia [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 
March 2009.
  45.  Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety 
of sitagliptin and metformin as initial combination therapy and as 
  monotherapy over 2 years in patients with type 2 diabetes. Diabetes 
Obes Metab. 2010;12(5):442–451.
  46.  Seck T, Nauck M, Sheng D, et al. Safety and efficacy of   treatment with 
sitagliptin or glipizide in patients with type 2 diabetes   inadequately 
controlled on metformin: a 2-year study. Int J Clin Pract. 2010; 
64(5):562–576.
  47.  Pfützner A, Paz-Pacheco E, Berglind N, Allen E, Frederich B, 
Chen R. Saxagliptin initial combination with metformin provides 
sustained glycemic control and is well tolerated in patients with type 
2 diabetes: 76-week results. Abstract presented at the 70th Scientific 
  Sessions of the American Diabetes Association. Diabetes. 2010; 
Orlando, FL. 64-OR.
  48.  Ravichandran S, DeFronzo R, Garber AJ, et al. Once-daily saxagliptin 
added to metformin provides sustained glycemic control and is well 
tolerated over 102 weeks in patients with type 2 diabetes. Diabetologia. 
2009;52 Suppl 1:1–550. S60.
  49.  Chen R, Donovan M, Rusnak JM. Saxagliptin used as monotherapy or in 
combination with other antihyperglycemic agents does not significantly 
increase risk of hypoglycemia. Diabetes. 2009;58 Suppl 1:2082-P.
  50.  US Department of Health and Human Services FDA. Guidance for 
Industry diabetes mellitus-evaluating cardiovascular risk in new 
  antidiabetic therapies to treat type 2 diabetes. Dec 2008. Available 
from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance-
RegulatoryInformation/Guidances/ucm071627.pdf. Accessed Jun 21, 
2010.
  51.  Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assess-
ment of cardiovascular outcomes in the saxagliptin drug development 
program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27.
  52.  AstraZeneca; Bristol-Myers Squibb. Does saxagliptin reduce the risk 
of cardiovascular events when used alone or added to other diabetes 
medications (SAVOR- TIMI 53). In: ClinicalTrials.gov [Internet]. 
Bethesda, MD: National Library of Medicine (US). 2010-[cited 2010 
May 5]. Available from: http://www.clinicaltrials.gov/ct2/show/
NCT01107886 NLM Identifier: NCT01107886.
  53.  Pollack M, Chastek B, Williams SA. Impact of treatment complexity 
on adherence and glycemic control: an analysis of oral anti-diabetic 
agents. Presented at International Society for Pharmacoeconomics 
and Outcomes Research 14th Annual International Meeting; 2009 May 
16–20; Orlando, FL. PDB36.
  54.  Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of Ameri-
can Diabetes Association clinical practice recommendations among U.S. 
adults with diabetes, 1999–2002: The National Health and Nutrition 
Examination Survey. Diabetes Care. 2006;29(3):531–537.